FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
This article was originally published in The Pink Sheet Daily
Executive Summary
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.